Plasma Metabolic Features Associated with Developmental Regression in Autism Spectrum Disorder: A Pilot Untargeted Metabolomics Study
International Journal of Molecular Sciences · 04.08.2026 · 27 (15) · 6995
DOI: 10.3390/ijms27156995 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.08.2026. Verfasst von Cihan Aslan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child and Adolescent Psychiatry, Faculty of Medicine, Hacettepe University, Ankara 06230, Türkiye. Hauptthemen laut MEDLINE: Metabolomics, Autism Spectrum Disorder, Metabolome. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Developmental regression, the loss of previously acquired language and social skills during the second year of life, affects 20–40% of children with autism spectrum disorder (ASD), yet its metabolic underpinnings remain poorly defined. Existing metabolomics studies have focused on amino acid and acylcarnitine alterations, leaving the eicosanoid, sphingolipid, and glycoconjugate axes largely unexamined. Plasma from 25 children with regressive ASD (REG+), 27 with non-regressive ASD (REG−), and 21 typically developing controls (aged 2–6 years) was profiled using untargeted Q-TOF LC/MS (Agilent 6530, ESI+ mode, 100–1700 m/z). From 6657 detected features, a stepwise curation pipeline combining statistical significance (raw p < 0.05 with Benjamini–Hochberg FDR correction, q < 0.05; FC > 1.5), analytical plausibility, endogenous origin verification, and literature-based directional alignment yielded a prioritized set of 14 annotated metabolic features. Exploratory PLS-DA (Partial Least-Squares Discriminant Analysis) visualization showed separation among the three groups within the present dataset; however, diagnostic or predictive performance was not evaluated. The 14-feature panel clustered along four biochemical axes. A feature putatively annotated as prostaglandin E3 (PGE3) showed a 7.13-fold reduction in REG+ versus controls (1.58-fold in REG−; FC REG+/REG− = 4.52). N-Acetylneuraminosyl-(α2-6)lactosamine and aspartylglycosamine were decreased 4.44-fold and 5.42-fold in REG+, respectively, with regression-specific amplification (FC REG+/REG− > 2.0). Six sphingolipid–myelin metabolites showed coordinated biosynthetic depletion and catabolic elevation in both ASD groups without regression specificity. DHEA-S exhibited the largest subgroup differential (FC REG+/REG− = 8.89), with paradoxically greater depletion in the non-regressive group. This exploratory study identified several plasma metabolic features showing abundance differences among children with REG+, REG−, and typically developing controls. These findings are hypothesis-generating and require confirmation using authenticated standards, targeted quantitative methods, and independently recruited cohorts before any diagnostic, predictive, or therapeutic relevance can be established.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Child and Adolescent Psychiatry, Faculty of Medicine, Hacettepe University, Ankara 06230, Türkiye.
- Department of Analytical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara 06100, Türkiye.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara 06100, Türkiye.
- Department of Bioengineering, Graduate School of Science and Engineering, Hacettepe University, Ankara 06800, Türkiye.
- Department of Development and Regeneration, KU Leuven, Leuven 3000, Belgium.
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven 3000, Belgium.
ORCID-Profile: Ozan Kaplan, Nadir Yalçın, Bilge Başak Fidan, Mustafa Çelebier, Karel Allegaert
Zitieren
APA
Aslan, C., Kaplan, O., Yalçın, N., Fidan, B. B., Çelebier, M., Ünal, D., & Allegaert, K. (2026). Plasma Metabolic Features Associated with Developmental Regression in Autism Spectrum Disorder: A Pilot Untargeted Metabolomics Study. International Journal of Molecular Sciences, 27(15), 6995. https://doi.org/10.3390/ijms27156995
Vancouver
Aslan C, Kaplan O, Yalçın N, Fidan BB, Çelebier M, Ünal D, et al. Plasma Metabolic Features Associated with Developmental Regression in Autism Spectrum Disorder: A Pilot Untargeted Metabolomics Study. International Journal of Molecular Sciences. 2026;27(15):6995. doi:10.3390/ijms27156995
BibTeX
@article{Aslan2026,
author = {Aslan, Cihan and Kaplan, Ozan and Yalçın, Nadir and Fidan, Bilge Başak and Çelebier, Mustafa and Ünal, Dilek and Allegaert, Karel},
title = {Plasma Metabolic Features Associated with Developmental Regression in Autism Spectrum Disorder: A Pilot Untargeted Metabolomics Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {15},
pages = {6995},
doi = {10.3390/ijms27156995}
}
EUVIMED